| Literature DB >> 35214126 |
Evgeny K Apartsin1,2,3,4, Nadezhda Knauer3,5,6, Ulf Dietrich Kahlert7, Anne-Marie Caminade1,2.
Abstract
Dendritic molecules bearing metal complexes in their structure (metallodendrimers and metallodendrons) are considered prospective therapeutic entities. In particular, metallodendrons raise interest as antitumor agents for the treatment of poorly curable or drug-resistant tumors. Herein, we have synthesized amphiphilic triazine-phosphorus dendrons bearing multiple copper (II) or gold (III) complexes on the periphery and a branched hydrophobic fragment at the focal point. Due to their amphiphilic nature, metallodendrons formed single micelles (mean diameter ~9 nm) or multi-micellar aggregates (mean diameter ~60 nm) in a water solution. We have tested the antitumor activity of amphiphilic metallodendrons towards glioblastoma, a malignant brain tumor with a notoriously high level of therapy resistance, as a model disease. The metallodendrons exhibit higher cytotoxic activity towards glioblastoma stem cells (BTSC233, JHH520, NCH644, and SF188 cell lines) and U87 glioblastoma cells (IC50 was 3-6 µM for copper-containing dendron and 11-15 µM for gold-containing dendron) in comparison with temozolomide (IC50 >100 µM)-the clinical standard of care for glioblastoma. Our findings show the potential of metallodendron-based nanoformulations as antitumor entities.Entities:
Keywords: copper; cytotoxicity; dendrons; gold; metallodrugs; nanomedicine; phosphorus; supramolecular associates; tumor stem cells
Year: 2022 PMID: 35214126 PMCID: PMC8880151 DOI: 10.3390/pharmaceutics14020393
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Synthesis of amphiphilic triazine-phosphorus metallodendrons. Conditions: (i) n-C12H25NH2, CHCl3, NaOH (aq.), 90%; (ii) tyramine, toluene, 110 °C, 95%; (iii) K2CO3, acetonitrile, 0 °C, 60%; (iv) AB5, K2CO3, acetonitrile, 75 °C, 93%; () 2-hydrazinopyridine, THF, 60 °C, 85%; (vi) CuCl2 or AuCl3, DMF, 60 °C, 54% or 40%.
Figure 2Particle size distribution in CuD and AuD solutions (left). TEM images of metallodendrons (right). Scale bar is 50 nm.
Figure 3Profiles of the cell viability (MTT assay) after incubation with CuD metallodendrons and temozolomide (TMZ). NTC—non-treated control. Data are presented as mean ± S.D. * p < 0.05, ** p < 0.01 CuD vs. AuD; # p < 0.05, ## p < 0.01 CuD vs. TMZ.
Figure 4Profiles of the cell viability (MTT assay) after incubation with AuD metallodendrons and temozolomide (TMZ). NTC—non-treated control. Data are presented as mean ± S.D. * p < 0.05, ** p < 0.01 CuD vs. AuD; § p < 0.05, §§ p < 0.01 AuD vs. TMZ.
IC50 values of metallodendrons and temozolomide (TMZ).
| Cell Line | IC50, µM | ||
|---|---|---|---|
| CuD | AuD | TMZ | |
| BTSC233 | 3.2 ± 0.3 | 11.5 ± 2.9 | n/a 1 |
| JHH520 | 4.8 ± 1.1 | 6.4 ± 2.0 | n/a |
| NCH644 | 5.9 ± 0.8 | 11.3 ± 2.8 | n/a |
| SF188 | 0.34 ± 0.21 | 12.3 ± 2.5 | ~125 2 |
| U87 (adherent) | 4.7 ± 3.0 | 15.0 ± 3.6 | n/a |
| U87 (suspension) | 11.1 ± 3.8 | 14.9 ± 2.8 | n/a |
1 IC50 could not be determined; 2 value predicted from data fitting.